Silymarin decreases liver stiffness associated with gut microbiota in patients with metabolic dysfunction-associated steatotic liver disease: a randomized, double-blind, placebo-controlled trial.
- 2024-08-03
- RCT · n = 83
- Lipids in health and disease 23(1)
- Yufeng Jin
- Xin Wang
- Ke Chen
- Yu Chen
- Lixin Zhou
- Yupeng Zeng
- Yuqing Zhou
- Zhijun Pan
- Di Wang
- Zhongxia Li
- Yongqian Liang
- Wenhua Ling
- Dan Li
- PubMed: 39097726
- DOI: 10.1186/s12944-024-02220-y
- High evidence
- Clinical
other biochemical indicators (aminotransferases, total bilirubin, glucose and lipid parameters, hsCRP, SOD, and UA)
- Effect
- Neutral
- Effect size
- Small
- Significant
- No
- Dose
- 103.2 mg/d